QuidelOrtho Co. (NASDAQ:QDEL) Shares Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its position in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 143.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,046,649 shares of the company’s stock after acquiring an additional 617,592 shares during the quarter. QuidelOrtho accounts for approximately 0.6% of Segall Bryant & Hamill LLC’s portfolio, making the stock its 28th largest holding. Segall Bryant & Hamill LLC owned about 1.56% of QuidelOrtho worth $46,628,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC acquired a new position in shares of QuidelOrtho during the 3rd quarter worth $605,000. State Street Corp grew its position in QuidelOrtho by 16.9% during the third quarter. State Street Corp now owns 1,907,898 shares of the company’s stock worth $87,000,000 after buying an additional 275,522 shares during the period. FMR LLC increased its holdings in QuidelOrtho by 28.0% in the third quarter. FMR LLC now owns 1,256,356 shares of the company’s stock valued at $57,290,000 after buying an additional 274,633 shares in the last quarter. Merit Financial Group LLC purchased a new position in QuidelOrtho in the fourth quarter valued at about $301,000. Finally, Principal Financial Group Inc. lifted its position in shares of QuidelOrtho by 64.5% during the 3rd quarter. Principal Financial Group Inc. now owns 272,037 shares of the company’s stock valued at $12,405,000 after acquiring an additional 106,642 shares during the period. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Stock Up 1.6 %

QDEL opened at $36.51 on Tuesday. The firm has a market cap of $2.46 billion, a P/E ratio of -1.21 and a beta of 0.10. The business’s fifty day simple moving average is $40.62 and its 200 day simple moving average is $41.65. QuidelOrtho Co. has a 52 week low of $29.74 and a 52 week high of $49.45. The company has a quick ratio of 0.69, a current ratio of 1.22 and a debt-to-equity ratio of 0.71.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. As a group, equities research analysts anticipate that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on QDEL. Jefferies Financial Group initiated coverage on QuidelOrtho in a report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 price target on the stock. Royal Bank of Canada lowered their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating on the stock in a report on Thursday, February 13th. StockNews.com downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. UBS Group boosted their price objective on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a research report on Thursday, February 13th. Finally, Citigroup upgraded shares of QuidelOrtho from a “neutral” rating to a “buy” rating and raised their target price for the company from $44.00 to $50.00 in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $51.20.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.